Shaker Investments LLC OH acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter, Holdings Channel reports. The fund acquired 6,400 shares of the medical research company’s stock, valued at approximately $647,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRL. Bbva Compass Bancshares Inc. boosted its position in Charles River Laboratories International by 0.8% in the second quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock valued at $607,000 after buying an additional 50 shares during the last quarter. World Asset Management Inc boosted its position in Charles River Laboratories International by 2.2% in the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after buying an additional 59 shares during the last quarter. Cardinal Capital Management boosted its position in Charles River Laboratories International by 1.1% in the first quarter. Cardinal Capital Management now owns 7,035 shares of the medical research company’s stock valued at $633,000 after buying an additional 76 shares during the last quarter. State Treasurer State of Michigan boosted its position in Charles River Laboratories International by 0.5% in the first quarter. State Treasurer State of Michigan now owns 19,200 shares of the medical research company’s stock valued at $1,727,000 after buying an additional 100 shares during the last quarter. Finally, Utah Retirement Systems boosted its position in shares of Charles River Laboratories International by 1.2% in the first quarter. Utah Retirement Systems now owns 8,597 shares of the medical research company’s stock worth $773,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 95.81% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at 99.53 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $102.32. The stock has a 50 day moving average price of $99.43 and a 200-day moving average price of $90.83. The stock has a market cap of $4.74 billion, a PE ratio of 29.13 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The business had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The company’s revenue was up 25.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.98 earnings per share. On average, analysts expect that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase program on Wednesday, May 10th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/shaker-investments-llc-oh-acquires-new-stake-in-charles-river-laboratories-international-inc-crl.html.

A number of research analysts have recently weighed in on CRL shares. Jefferies Group LLC restated a “buy” rating and issued a $106.00 price target on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. restated a “neutral” rating and issued a $104.00 price target (up previously from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. Barclays PLC set a $90.00 price target on Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Credit Suisse Group restated a “neutral” rating and issued a $95.00 price target (up previously from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $97.06.

In other news, insider David Ross Smith sold 945 shares of the business’s stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $95.00, for a total transaction of $89,775.00. Following the sale, the insider now directly owns 14,203 shares of the company’s stock, valued at $1,349,285. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George Massaro sold 1,130 shares of the business’s stock in a transaction on Friday, May 12th. The stock was sold at an average price of $88.30, for a total value of $99,779.00. Following the sale, the director now directly owns 15,831 shares in the company, valued at $1,397,877.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 80,499 shares of company stock valued at $7,946,191. Insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.